Skip to content

The effect of L-arabinose on glycaemic responses in subjects at risk of developing type II diabetes

The effect of L-arabinose on glycaemic responses in subjects at risk of developing type II diabetes - Ara4-study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON45845
Enrollment
18
Registered
2018-10-16
Start date
2018-11-16
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes type 2 metabolic diseases

Interventions

Addition of 10% arabinose to a sucrose drink. And we will explore the addition of 15% of arabinose to a normal diet.

Sponsors

Wageningen Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Age between 55-80 years * BMI * 25.0 kg/m2 * Impaired fasting glucose (IFG; fasting glucose * 5.6 and

Exclusion criteria

Exclusion criteria: * Diagnosed diabetes, * Diagnosed liver, pancreas or endocrine diseases which could affect the study results, * Having gastro-intestinal problems, * Use of medication or supplements which could affect the study results (Moreover, chronic medication and supplements should be used as normal when they donot affect the study results), * Allergy, intolerance or oversensitivity for food products, * Sensitive to medical skin adhesives, * Following a medically prescribed, low energy or low carbohydrate diet, * Unwilling to consume the provided diets, * >5 kg weight change during the last 3 months, * Current antibiotics usage or in the two months prior to the screening session, * Excessive alcohol consumption (>21 glasses/week on average for men and >14 glasses/week for women), * Having blood vessels that are too difficult for inserting a cannula, as judged by the study nurse, * Not normal haemoglobin (Hb) concentration:

Design outcomes

Primary

MeasureTime frame
Glycaemic response

Secondary

MeasureTime frame
Insulin response, glucagon response, satiety response, glucose monitoring, gastro-intestinal tolerance

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)